Multidimensional immunomodulation

Journal of Immunotoxicology

Volumn 1, Issue 2, 2004, Pages 123-129

  House, Robert V ^a   Hastings, Kenneth L ^b  

^a DynPort Vaccine Company LLC   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33749562537     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.1080/15476910490503646     Document Type: Article

References (37)

1. Abo, T., and Kawamura, T. 2002. Immunomodulation by the autonomic nervous system: Therapeutic approach for cancer, collagen diseases, and inflammatory bowel diseases. Ther. Apher. 6:348-357. (Pubitemid 35192325)
2. Bondanza, A., Zimmermann, V. S., Dell'Antonio, G., Cin, E. D., Balestrieri, G., Tincani, A., Amoura, Z., Piette, J. C., Sabbadini, M. G., Rovere-Querini, P., and Manfredi, A. A. 2004. Requirement of dying cells and environmental adjuvants for the induction of autoimmunity. Arthritis Rheum. 50:549-1560.
3. Chen, W., Thoburn, C. J., Miura, Y., Sommer, M., Hruban, R., Qian, Z., Baldwin, W., and Hess, A. D. 2001. Autoimmune-mediated vasculopathy. Clin. Immunol. 100:57-70.
4. Damoiseaux, J. G. M., Beijleveld, L. J. J., and Van Breda Vriesman, P. J. C. 1997. Multiple effects of cyclosporin A on the thymus in relation to T-cell development and autoimmunity. Clin. Immunol. Immunopathol. 82:197-202. (Pubitemid 27128304)
5. Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y. T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S. P., Richardson, P. G., Schlossman, R. L., Morgan, G. J., Muller, G. W., Stirling, D. I., and Anderson, K. C. 2001. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216.
6. Dean, J. H., House, R. V., and Luster, M. I. 2001. Immunotoxicology: Effects of, and response to, drugs and chemicals. In Principles and Methods of Toxicology, Fourth Edition (A. W. Hayes, ed.), pp. 1415-1450, Taylor & Francis, London.
7. Di Paolo, S., Schena, A., Morrone, L. F., Manfredi, G., Stallone, G., Derosa, C., Procino, A., and Schena, F. P. 2000. Immunologic evaluation during the first year of life of infants born to cyclosporine-treated female kidney transplant recipients. Transplantation 69:2049-2054. (Pubitemid 30395032)
8. Friedman, E. M., and Lawrence, D. A. 2002. Environmental stress mediates changes in neuroimmunological interactions. Toxicol. Sci. 67:4-10. (Pubitemid 34520803)
9. Frieri, M. 2003. Neuroimmunology and inflammation: Implications for therapy of allergic and autoimmune diseases. Ann. Allergy Asthma Immunol. 90(6 Supp. 3):34-40. (Pubitemid 36712688)
10. Fuchs, B. A., and Sanders, V. M. 1994. The role of brain-immune interactions in immunotoxicology. Crit. Rev. Toxicol. 24:151-176.
11. Hastings, K. L. 2002. Implications of the new FDA/CDER immunotoxicology guidance for drugs. Int. Immunopharmacol. 2:1613-1618. (Pubitemid 35223242)
12. Hilts, P. J. 2003. Protecting America's Health. The FDA, Business, and One Hundred Years of Regulation. Alfred A. Knopf, New York.
13. House, R. V. 2002. Preclincial immunotoxicity assessment of cytokine therapeutics. Biotechnology and Safety Assessment, Third Edition, (J. A. Thomas and R. L. Fuchs, Eds.), pp. 191-231, Academic Press, San Diego.
14. Jenkins, M. K., Schwartz, R. H., and Pardoll, D. M. 1988. Effects of cyclosporine A on T cell development and clonal deletion. Science 241:1655-1658.
15. Kahan, B. D. 2003. Individuality: The barrier to optimal immunosuppression. Nat. Rev. Immunol. 3:831-838. (Pubitemid 37328661)
16. Karrow, N. A., McCay, J. A., Brown, R. D., Musgrove, D. L., Pettit, D. A., Munson, A. E., Germolec, D. R., and White, K. L., Jr. 2000. Thalidomide stimulates splenic IgM antibody response and cytotoxic Tlymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice. Toxicol. Appl. Pharmacol. 165:237-244. (Pubitemid 30429907)
17. Kimber, I., Basketter, D. A., Gerberick, G. F., and Dearman, R. A. 2002. Allergic contact dermatitis. Int. Immunopharmacol. 2:201-211. (Pubitemid 34075411)
18. Kumar, S., Jones, T. R., Oakley, M. S., Zheng, H., Kuppusamy, S. P., Taye, A., Krieg, A. M., Stowers, A. W., Kaslow, D. C., and Hoffman, S. L. 2004. CpG oligodeoxy-nucleotide and montanide ISA51adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect. Immun. 72:949-957. (Pubitemid 38166675)
19. Matzinger, P. 1998. An innate sense of danger. Sem. Immunol. 10:399-415. (Pubitemid 28499554)
20. Naisbitt, D. J. 2004. Drug hypersensitivity reactions in skin: Understanding mechanisms and the development of diagnostic and predictive tests. Toxicology 194:179-196. (Pubitemid 37542452)
21. Nevo, U., Golding, I., Neumann, A. U., Schwartz, M., and Akselrod, S. 2004. Autoimmunity as an immune defense against degenerative processes: A primary mathematical model illustrating the bright side of autoimmunity. J. Theor. Biol. 227:583-592. (Pubitemid 38376174)
22. Park, B. K., and Kitteringham, N. R. 1990. Drug-protein conjugation and its immunological consequences. Drug Metab. Rev. 22:87-144. (Pubitemid 20211495)
23. Pieters, R., Ezendam, J., and Nierkens, S. 2003. Chemical-specific properties co-determine the typeofadverse immune response. Autoimmun. Rev. 2:25-29. (Pubitemid 37443868)
24. Pirmohamed, M., and Park, B. K. 2001. HIV and drug allergy. Curr. Opin. Allergy Clin. Immunol. 1:311-316.
25. Pozo, D. 2003. VIP-and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol. Med. 9:211-217. (Pubitemid 36713391)
26. Raison, C. L., and Miller, A. H. 2001. The neuroimmunology of stress and depression. Semin. Clin. Neuropsychiatry 6:277-294.
27. Rieux-Laucat, F., Fischer, A., and Le Deist, F. 2003. Cell-death signaling and human disease. Curr. Opin. Immunol. 15:325-331. (Pubitemid 36645110)
28. Riminton, D. S., Kandasamy, R., Dravec, D., Basten, A., and Baxter, A. G. 2004. Dermal enhancement: Bacterial products on intact skin induce and augment organ-specific autoimmune disease. J. Immunol. 172:302-309. (Pubitemid 38020484)
29. Sakaguchi, S., and Sakaguchi, N. 1989. Organ-specific autoimmune disease induced in mice by elimination of T-cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease. J. Immunol. 142:471-480. (Pubitemid 19039964)
30. Shelburne, S. A., III, and Hamill, R. J. 2003. The immune reconstitution inflammatory syndrome. AIDS Rev. 5:67-79.
31. Togias, A. 2004. Systemic effects of local allergic disease. J. Allergy Clin. Immunol. 113:S8-S14. (Pubitemid 38091409)
32. Uetrecht, J. P. 1999. New concepts in immunology relevant to idiosyncratic drug reactions: The "Danger Hypothesis" and innate immune system. Chem. Res. Toxicol. 12:387-395. (Pubitemid 29352401)
33. van Zijverden, M., van der Pijl, A., Bol, M., van Pinxteren, F. A., de Haar, C., Penninks, A. H., van Loveren, H., and Pieters, R. 2000. Diesel exhaust, carbon black, and silica particles display distinct Th1/Th2 modulating activity. Toxicol. Appl. Pharmacol. 168:131-139.
34. Vos, J. G. 1977. Immune suppression as related to toxicology. CRC Crit. Rev. Toxicol. 5:67-101.
35. Wen, L., Peng, J., Li, Z., and Wong, F. S. 2004. The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets. J. Immunol. 172:3173-3180. (Pubitemid 38263708)
36. Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., and Engert, A. 1999. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94:2217-2224. (Pubitemid 29467667)
37. Zheng, L., Trageser, C. L., Willerford, D. M., and Lenardo, M. J. 1998. T-Cell growth cytokines cause the superinduction of molecules mediating antigeninduced T-lymphocyte death. J. Immunol. 160:763-769. (Pubitemid 28049317)